AVLN News
Archived Headlines
- US IPO Week Ahead: Biotechs, mining, and Bill Ackman deals set to debut 04/24/26
- Pulmonary fibrosis biotech Avalyn Pharma sets terms for $201 million IPO 04/23/26
- US IPO Weekly Recap: Pipeline swells with sizable IPO filings as Metals Royalty direct lists 04/10/26
- Pulmonary fibrosis biotech Avalyn Pharma files for a $100 million IPO 04/08/26
US IPO Weekly Recap: Biotech, early-stage mining, and Bill Ackman close out the April IPO market
Four IPOs priced this past week, led by three sizable biotechs. They were joined by 11 blank check listings. Coagulation disorder biotech Hemab Therapeutics (COAG) upsized and priced at the high end to raise $302 million at an $849 million market cap. Hemab...read more
Renaissance Capital’s April IPO Market Update
Thirteen IPOs raised a combined $7.3 billion in April, joined by two direct listings. While surging volatility in March weighed on new issuance early on, activity ended in line with April’s 10-year historical average by deal count (15) but well above by...read more
Pulmonary fibrosis biotech Avalyn Pharma prices upsized IPO at $18, the high end of the range
Avalyn Pharma, a Phase 2 biotech developing inhaled medicines for rare respiratory diseases, raised $300 million by offering 16.7 million shares at $18, the high end of the $16 to $18 range. The company originally filed to offer 11.8 million shares at $16 to...read more
Pulmonary fibrosis biotech Avalyn Pharma increases shares offered by 41% ahead of $283 million IPO
Avalyn Pharma, a Phase 2 biotech developing inhaled medicines for rare respiratory diseases, raised the proposed deal size for its upcoming IPO on Wednesday. The Boston, MA-based company now plans to raise $283 million by offering 16.7 million shares at a...read more